Catalyst Wire Dossier Catalyst Wire Dossier

ENFLONSIA

CLESROVIMAB · Merck Sharp & Dohme LLC
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for ENFLONSIA, covering 2025-06-09 to 2026-06-04. Get the full timeline:

Most recent: EMA Authorised: Enflonsia (clesrovimab) — Merck Sharp Dohme Limited

See pricing